Phase 2 Prostate Cancer Trial, Recruiting NCT07455903 Sponsor: Baptist Health South Florida Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT07455903
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a consent form before the study begins
  • Men aged 18 years or older
  • People whose general health and ability to carry out daily activities meets a certain level of functioning (confirm with trial site what this means for a specific situation)
  • People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma) through a tissue sample, and for whom surgery to remove the prostate is considered an option
  • People whose prostate cancer has at least one high-risk feature, such as: the tumour has grown beyond the prostate (stage cT3 or cT4); a high aggressiveness score on biopsy (Gleason score of 8, 9, or 10); or a PSA blood test result above 20 ng/mL
  • People whose lymph nodes appear cancer-free on a specialised type of scan called a PSMA PET/CT (with some exceptions around borderline findings — confirm with trial site)
  • People who are willing to use barrier contraception (such as a condom) plus another effective contraceptive method during sexual activity with a pregnant person or someone who could become pregnant, until one week after completing the study scans
  • People whose blood test results during screening show healthy enough levels of red blood cells, white blood cells, and platelets (confirm with trial site for specific values)

Who may not be able to join:

  • People with a known allergy or sensitivity to the scan substance used in this trial (18F-flotufolastat)
  • People who are unable to receive hormone therapy to reduce testosterone (androgen deprivation therapy)
  • People whose prostate cancer has rare or unusual cell types beyond standard adenocarcinoma
  • People whose scans show cancer has spread to bones, organs, or lymph nodes in certain areas of the body
  • People with significantly reduced kidney function
  • People who have previously had radiation treatment for prostate cancer
  • People who have experienced serious heart problems — such as a heart attack, severe chest pain, heart failure, or significant irregular heartbeat — within the past 6 months
  • People with uncontrolled high blood pressure, uncontrolled diabetes, lung disease requiring oxygen, chronic liver disease, or untreated HIV
  • People who have had another type of cancer in the past 5 years (though people who have had certain treated skin cancers may still be eligible — confirm with trial site)
  • People with severe or uncontrolled active infections
  • People currently receiving chemotherapy or other cancer-killing treatments for a different cancer
  • People who would not be able to complete both the second PSMA scan and the surgical procedure required by the study
  • People with any other condition that the study doctor considers would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Rohan Garje, M.D., Miami Cancer Institute at Baptist Health, Inc.

Phone: 786-596-2000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Baptist Health South Florida
Registry
ClinicalTrials.gov
Start date
23 April 2026
Est. completion
1 October 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Objective response rate (ORR) based on PSMA PET; ORR based on Response Evaluation Criteria in PSMA Imaging (RECIP 1.0)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov